Dr. John M. Flack, MD, MPH
Internal Medicine (Hypertension Specialist Physician)
- Medicare participating
At a glance
- Years since graduation
- 44
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 44
Licensed in Illinois since 2015, according to the Illinois Department of Financial and Professional Regulation. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hypertension Specialist Physician primary
IL license 036-138254 (first issued 2015; active) -
Internal Medicine Physician
IL license 036-138254 (first issued 2015; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Memorial Medical Center Springfield, IL
Medical groups
- Siu Physicians and Surgeons Inc (314 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 44
- Services billed
- 55
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 31 | 24 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Olmesartan Medoxomil Other prescribers in Springfield, IL | 223 |
| Chlorthalidone Other prescribers in Springfield, IL | 140 |
| Amlodipine Besylate Other prescribers in Springfield, IL | 127 |
| Allopurinol Other prescribers in Springfield, IL | 126 |
| Indapamide Other prescribers in Springfield, IL | 108 |
| Metoprolol Succinate Other prescribers in Springfield, IL | 78 |
| Entresto (sacubitril/valsartan) Other prescribers in Springfield, IL | 68 |
| Isosorbide Mononitrate Er (isosorbide mononitrate) Other prescribers in Springfield, IL | 47 |
| Amiloride Hcl | 43 |
| Spironolactone Other prescribers in Springfield, IL | 38 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 4 companies reported 33 payments worth $25,636 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $15,624 |
|---|---|
| Azurity Pharmaceuticals, Inc. | $8,416 |
| Recor Medical Inc | $1,543 |
| Idorsia Pharmaceuticals US Inc | $52.28 |
| Consulting Fee | $22,655 |
|---|---|
| Travel and Lodging | $2,155 |
| Food and Beverage | $826 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Azurity Pharmaceuticals, Inc. Dec 13, 2025 | Consulting Fee WIDAPLIK · ANTI-HYPERTENSIVE | $7,225 |
| AstraZeneca Pharmaceuticals LP Sep 19, 2025 | Consulting Fee | $2,500 |
| AstraZeneca Pharmaceuticals LP Apr 25, 2025 | Consulting Fee | $2,148 |
| AstraZeneca Pharmaceuticals LP Aug 22, 2025 | Consulting Fee | $2,000 |
| AstraZeneca Pharmaceuticals LP Dec 14, 2025 | Consulting Fee | $1,500 |
| AstraZeneca Pharmaceuticals LP Jan 29, 2025 | Consulting FeeCompany’s descriptionResearch Related Service | $1,074 |
| AstraZeneca Pharmaceuticals LP Aug 26, 2025 | Consulting FeeCompany’s descriptionResearch Related Service | $1,074 |
| AstraZeneca Pharmaceuticals LP Oct 21, 2025 | Consulting FeeCompany’s descriptionResearch Related Service | $1,074 |
| AstraZeneca Pharmaceuticals LP Aug 5, 2025 | Consulting FeeCompany’s descriptionResearch Related Service | $1,074 |
| AstraZeneca Pharmaceuticals LP May 22, 2025 | Consulting FeeCompany’s descriptionResearch Related Service | $1,031 |
All 22 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP Dec 14, 2025 | Consulting Fee | $1,500 |
| Azurity Pharmaceuticals, Inc. Dec 13, 2025 | Consulting Fee WIDAPLIK · ANTI-HYPERTENSIVE | $7,225 |
| Azurity Pharmaceuticals, Inc. Dec 13, 2025 | Travel and Lodging WIDAPLIK · ANTI-HYPERTENSIVE · travel to AURORA, CO | $392 |
| Azurity Pharmaceuticals, Inc. Dec 13, 2025 | Travel and Lodging WIDAPLIK · ANTI-HYPERTENSIVE · travel to AURORA, CO | $275 |
| Azurity Pharmaceuticals, Inc. Dec 13, 2025 | Travel and Lodging WIDAPLIK · ANTI-HYPERTENSIVE · travel to AURORA, CO | $214 |
| Azurity Pharmaceuticals, Inc. Dec 13, 2025 | Travel and Lodging WIDAPLIK · ANTI-HYPERTENSIVE · travel to AURORA, CO | $159 |
| Recor Medical Inc Dec 8, 2025 | Travel and Lodging Paradise Ultrasound Renal Denervation System · Devices · travel to Cupertino, CA · in-kind | $8.04 |
| Recor Medical Inc Dec 4, 2025 | Travel and Lodging Paradise Ultrasound Renal Denervation System · Devices · travel to Palo Alto, CA · in-kind | $694 |
| Recor Medical Inc Dec 4, 2025 | Travel and Lodging Paradise Ultrasound Renal Denervation System · Devices · travel to Palo Alto, CA · in-kind | $24.11 |
| Recor Medical Inc Dec 3, 2025 | Travel and Lodging Paradise Ultrasound Renal Denervation System · Devices · travel to Palo Alto, CA · in-kind | $32.14 |
| AstraZeneca Pharmaceuticals LP Oct 21, 2025 | Consulting FeeCompany’s descriptionResearch Related Service | $1,074 |
| AstraZeneca Pharmaceuticals LP Sep 19, 2025 | Consulting Fee | $2,500 |
| Recor Medical Inc Sep 17, 2025 | Travel and Lodging Paradise Ultrasound Renal Denervation System · Devices · travel to St. Louis, MO · in-kind | $210 |
| Recor Medical Inc Sep 17, 2025 | Travel and Lodging Paradise Ultrasound Renal Denervation System · Devices · travel to San Francisco, CA · in-kind | $147 |
| AstraZeneca Pharmaceuticals LP Aug 26, 2025 | Consulting FeeCompany’s descriptionResearch Related Service | $1,074 |
| AstraZeneca Pharmaceuticals LP Aug 22, 2025 | Consulting Fee | $2,000 |
| AstraZeneca Pharmaceuticals LP Aug 5, 2025 | Consulting FeeCompany’s descriptionResearch Related Service | $1,074 |
| AstraZeneca Pharmaceuticals LP May 22, 2025 | Consulting FeeCompany’s descriptionResearch Related Service | $1,031 |
| AstraZeneca Pharmaceuticals LP Apr 25, 2025 | Consulting Fee | $2,148 |
| AstraZeneca Pharmaceuticals LP Mar 2, 2025 | Consulting FeeCompany’s descriptionResearch Related Service | $972 |
| AstraZeneca Pharmaceuticals LP Feb 5, 2025 | Consulting FeeCompany’s descriptionResearch Related Service | $983 |
| AstraZeneca Pharmaceuticals LP Jan 29, 2025 | Consulting FeeCompany’s descriptionResearch Related Service | $1,074 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 2 companies. The companies reported $93,110 in research payments for these studies, mostly to the institutions running them.
- US GPS
Recor Medical Inc - A Randomised,Double Blind,Placebo Controlled,Parallel Group Study to Assess the Efficacy and Safety of Baxdrostat in Participants with Uncontrolled Hypertension on Two or More Medications including Participants with R…
AstraZeneca Pharmaceuticals LP - RADIANCE CAP
Recor Medical Inc - RADIANCE II
Recor Medical Inc
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.